The study lasts between 1.1 to 3.4 months (depending on when a migraine attack occurs during the treatment period). The study includes several key events:~Screening Visit (Day 1).~30-day Run-In Period (Days 1-30).~Randomization Visit (Days 31-37).~Treatment Period (Days 31-97): up to 60 days to treat a migraine at home.~End-of-Study Visit (Days 34 -104): 3 to 7 days after treatment.
The main objective of this study is to evaluate the safety and efficacy of an oral naltrexone-acetaminophen combination for the treatment of acute migraine and co-occurring anxiety in adults.